Clinical and immunological characteristics of newborn infants from mothers with cancers


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To provide the clinical characteristics of the health status and to assess the immune status of neonates born to mothers with cancer who had received chemotherapy during pregnancy. Subjects and methods. Pregnant women with cancer (n = 60) and their newborn infants (n = 64) underwent physical examination. Ultrasonography was used to examine the brain, abdominal organs, kidneys, and heart in ail the babies. Flow cytometry was employed to assess the composition of lymphocyte subpopulations in the umbilical cord blood of 27 newborn infants and in the venous blood of their mothers. Results. The babies born to women with cancer had lower weight and height and higher frequency of complications in the early neonatal period, which can be attributed to a lower gestational age due to premature delivery that necessitated a more aggressive therapy in the mother. The signs that stemmed from imbalance in the cellular component of immunity, which were manifested by decreases in the immunoregulatory index and in the count of B lymphocytes and by increases in the level of activated T lymphocytes and in that of lymphocytes ready for apoptosis, were observed in pregnant women with cancer who had received immunosuppressive therapy. The umbilical cord blood of their newborn infants displayed a reduction in the relative content of B lymphocytes in the absence of significant differences in the number of T lymphocytes in the control group. Conclusion. The satisfactory status of neonates, the course of the neonatal period, and the lack of considerable changes in the immune status of newborn infants from cancer mothers receiving chemotherapy may be indicative of the adequacy of the performed drug therapy necessary to suppress disease activity and to ensure a successful pregnancy.

Full Text

Restricted Access

About the authors

M. I Makieva

National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov

Email: m_makieva@oparina4.ru
neonatologist, pediatrician, the head of the clinical work of the department of newborns

N. K Matveeva

National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov

Email: matveeva_nk@mail.ru
candidate of biological science, senior researcher of clinical immunology laboratory

L. V Vanko

National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov

Email: lvanko@mail.ru
doctor of medicine, professor, leading research worker of clinical immunology laboratory

T. A Tsoi

National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov

Email: t_tsoy@oparina4.ru
neonatologist

A. S Zhukova

National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov

Email: a_belyaeva@oparina4.ru
research worker of clinical immunology laboratory

E. A Shatalova

National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov

Email: e_shatalova@oparina4.ru
neonatologist

E. S Polushkina

National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov

Email: e_polushkina@oparina4.ru
candidate of medicine sciences, obstetrician-gynecologist

M. V Averyanova

Pirogov Russian National Research Medical University

Email: marisha@mail.ru
6-year student

L. A Timofeeva

National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov

Email: leilatimofeeva@mail.ru,l_timofeeva@oparina4.ru
candidate of medicine sciences, the head of the department of newborns

L. V Krechetova

National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov

Email: k_l_v_@mail.ru
candidate of medicine sciences, head of clinical immunology laboratory

V. V Zubkov

National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov

Email: v_zubkov@oparina4.ru
Doctor of Medicine, Head of the Department of Neonatology and Pediatrics; Professor of the Department of Neonatology

P. G Shmakov

National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov; Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia

Email: r_shmakov@oparina4.ru
Doctor of Medicine, Head Physician

References

  1. Liu Y., Y. Liu, Wang Y., Chen X., Chen H., Zhang J. Malignancies associated with pregnancy: an analysis of 21 clinical cases. Irish. J. Med. Sci. 2015; 184(1): 175-81.
  2. Pavlidis N. Cancer and pregnancy: what should we know about the management with systemic treatment of pregnant women with cancer? Eur. J. Cancer. 2011; 47(Suppl. 3): S348-52.
  3. Паукер В.А., Шмаков Р.Г. Онкологические заболевания и беременность. Акушерство и гинекология. 2013; 11: 13-8. [Pauker W.A., Shmakov R.G. Cancer and pregnancy. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2013; (11): 13-8. (in Russian)]
  4. Cordoba O., Llurba E., Saura C., Rubio I., Ferrer Q., Cortés J., Xercavins J. Multidisciplinary approach to breast cancer diagnosed during pregnancy: Maternal and neonatal outcomes. Breast. 2013; 22(4): 515-9.
  5. Ko E.M., Van Le L. Chemotherapy for gynecologic cancers occurring during pregnancy. Obstet. Gynecol. Surv. 2011; 66(5): 291-8.
  6. Vandenbriele C., Dierickx D., Amant F., Delforge M. The treatment of hematologic malignancies in pregnancy. Facts Views Vis. Obgyn. 2010; 2(2): 74-87.
  7. Cordoba O., Llurba E., Cortés J., Sabadell M.D., Lirola J.L., Ferrer Q. et al. Complete pathological remission in a patient with hormonereceptor positive and c-erbB-2 expression-negative breast cancer treated with FAC chemotherapy during pregnancy. Tumori. 2010; 96(4): 629-32.
  8. Brewer M., Kueck A., Runowicz C.D. Chemotherapy in pregnancy. Clin. Obstet. Gynecol. 2011; 54(4): 602-18.
  9. Ives A.D., Saunders C.M., Semmens J.B. The Western Australian gestational breast cancer project: a population-based study of the incidence, management and outcomes. Breast. 2005; 14(4): 276-82.
  10. Hahn K.M., Johnson P.H., Gordon N., Kuerer H., Middleton L., Ramirez M. et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer. 2006; 107(6): 1219-26.
  11. Murthy R.K., Theriault R.L., Barnett C.M., Hodge S., Ramirez M.M., Milbourne A. et al. Outcomes of children exposed in utero to chemotherapy for breast cancer. Breast Cancer Res. 2014; 16(6): 500.
  12. Волочаева М.В., Шмаков Р.Г., Зубков В.В. Здоровье детей, рожденных женщинами с раком молочной железы, связанным с беременностью. Акушерство и гинекология. 2014; 7: 33-7. [Volochaeva M.V., Shmakov R.G., Zubkov V.V. The health of babies born to women with pregnancy-associated breast cancer. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2014; (7): 33-7. (in Russian)]
  13. Fenton T.R., Nasser R., Eliasziw M., Kim J.H., Bilan D., Sauve R. Validating the weight gain of preterm infants between the reference growth curve of the fetus and the term infant. BMC Pediatr. 2013; 13: 92.
  14. Motta M., Ciardelli L., Marconi M., Tincani A., Gasparoni A., Lojacono A., Chirico G. Immune system development in infants born to mothers with autoimmune disease, exposed in utero to immunosuppressive agents. Am. J. Perinatol. 2007; 24(8): 441-7.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies